Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Beta-BSM is an injectable, nanocrystalline calcium phosphate bone substitute material designed for the repair of bone defects. Developed by Etex Corporation, it is composed of a proprietary synthetic bone mineral that mimics the chemical and structural characteristics of natural bone mineral, specifically poorly crystalline hydroxyapatite (PCA). The material is supplied as a powder and a liquid that, when mixed, form a paste that can be injected directly into a bone void. Once injected, it hardens in situ at body temperature without significant heat generation. Beta-BSM acts as an osteoconductive scaffold, providing a structural matrix that allows for the infiltration of bone-forming cells and subsequent remodeling into native bone over time. It is primarily indicated for filling bone voids or gaps in the skeletal system that are not intrinsic to the stability of the bone structure, such as those found in the extremities, spine, and pelvis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Beta-BSM.